

Tarsier Pharma Raises Capital to Execute Phase-3 Clinical Trial

25 August, 2021

BioLight is proud to announce that on 24th August, 2021, Tarsier Pharma, one of its portfolio companies, reported to the Company that it has signed a fund raising and allotment of shares ("Investment Agreement") at a company value of \$100 million USD (prior to investment).

It should be noted in this context that the Company's initial investment in Tarsier Pharma in the amount of \$1 million USD was made in October 2019 at a company value of approximately \$20 million USD (prior to investment). Under the investment agreement, the Company retains its stake and accordingly invested \$ 250,000 USD in Tarsier Pharma.

To the best of the Company's knowledge, Tarsier Pharma is developing an innovative product, the TRS01, based on the technological platform for the treatment of eye-catching inflammatory eye diseases. The amount of investment raised is expected to be used primarily to fund a Phase III clinical trial in the TRS01 (which received IND² application approval and IRB³ approvals by the FDA) product.

Forward-looking information statement - The information and details contained in this report regarding the investment and expectations for the clinical trial (if any) Phase III of the TRS01 product as well as forecasts, dates, assessments and / or plans of the company and / or Tarsier Pharma in this regard, are "information Looking to the future "within the meaning of the Securities Law, 5728-1968, which involves high uncertainty, and is based, among other things, on third parties and many variables over which the company and / or Tarsier Pharma do not necessarily have control, and therefore such information and valuations may not materialize and / or will not materialize in full and / or will materialize in a manner materially different from what was initially estimated or observed, as well as the realization of any of the risk factors as specified in section 4.24 in Chapter A of the annual report, which may significantly affect the Company, together or separately in reference to the value of Tarsier Pharma as said.

About BioLight

BioLight Life Sciences Ltd. is a leading company investing in companies and managing projects relating to eye diseases and their treatment. BioLight's portfolio companies engage in advanced medical devices, medication, diagnostics and digital medicine and all exemplifying the enormous potential of innovation in the ophthalmological technologies. The Ophthalmic products developed by the companies in the BioLight group are aimed at innovative diagnosis and treatments for the needs of patient groups suffering from eye diseases. The different ophthalmic products are in various commercialization and clinical (or pre-clinical) phases.